Literature DB >> 7562470

Nebivolol vasodilates human forearm vasculature: evidence for an L-arginine/NO-dependent mechanism.

J R Cockcroft1, P J Chowienczyk, S E Brett, C P Chen, A G Dupont, L Van Nueten, S J Wooding, J M Ritter.   

Abstract

Nebivolol, a beta 1 selective adrenergic receptor antagonist with additional properties, is a racemic mixture of (S,R,R,R)- and (R,S,S,S)-enantiomers. We investigated its effects on human forearm vasculature. Blood flow was measured using venous occlusion plethysmography during brachial artery infusion of drugs. Interaction between nebivolol and the L-arginine/nitric oxide pathway was investigated via comparison with carbachol (an endothelium-dependent agonist) and nitroprusside, and by coinfusion of a competitive inhibitor of nitric oxide synthase, NG-monomethyl L-arginine (LNMMA) +/- L-arginine. Nebivolol (354 micrograms/min) increased blood flow by 91 +/- 18% (mean +/- SEM, n = 8, P < .01) whereas an equimolar dose of atenolol had no significant effect. L-NMMA (1 mg/min) inhibited vasodilation to nebivolol (by 65 +/- 10%) and carbachol (by 49 +/- 8%) to a significantly greater extent than it reduced responses to nitroprusside. Inhibition of nebivolol response by L-NMMA was abolished by L-arginine (62 +/- 11% inhibition by L-NMMA, 15 +/- 17% inhibition by L-NMMA with L-arginine, 10 mg/min, n = 8). Vasodilation caused by the (S,R,R,R)- and (R,S,S,S)-enantiomers was similar. We conclude that nebivolol vasodilates human forearm vasculature via the L-arginine/nitric oxide pathway.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7562470

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  64 in total

Review 1.  Beta-blockers in the management of hypertension in patients with type 2 diabetes mellitus: is there a role?

Authors:  F Dunne; M J Kendall; U Martin
Journal:  Drugs       Date:  2001       Impact factor: 9.546

Review 2.  Effects of antihypertensive drugs on endothelial dysfunction: clinical implications.

Authors:  Stefano Taddei; Agostino Virdis; Lorenzo Ghiadoni; Isabella Sudano; Antonio Salvetti
Journal:  Drugs       Date:  2002       Impact factor: 9.546

Review 3.  The role of Beta-blockers as first-line therapy in hypertension.

Authors:  Alberto Ranieri De Caterina; Antonio Maria Leone
Journal:  Curr Atheroscler Rep       Date:  2011-04       Impact factor: 5.113

4.  Effects of nebivolol therapy on endothelial functions in cardiac syndrome X.

Authors:  Fatma Kayaalti; Nihat Kalay; Emrullah Basar; Ertuğrul Mavili; Mustafa Duran; Ibrahim Ozdogru; Ali Dogan; Mehmet Tugrul Inanc; Mehmet Gungor Kaya; Ramazan Topsakal; Abdurrahman Oguzhan
Journal:  Heart Vessels       Date:  2010-03-26       Impact factor: 2.037

Review 5.  The latest generation of beta-blockers: new pharmacologic properties.

Authors:  Michala E Pedersen; John R Cockcroft
Journal:  Curr Hypertens Rep       Date:  2006-08       Impact factor: 5.369

6.  Effects of antihypertensive treatment on endothelial function.

Authors:  Agostino Virdis; Lorenzo Ghiadoni; Stefano Taddei
Journal:  Curr Hypertens Rep       Date:  2011-08       Impact factor: 5.369

Review 7.  The vasodilatory beta-blockers.

Authors:  Michala E Pedersen; John R Cockcroft
Journal:  Curr Hypertens Rep       Date:  2007-08       Impact factor: 5.369

8.  Pharmacological properties of nebivolol in man.

Authors:  L M Van Bortel; J N de Hoon; M J Kool; J A Wijnen; C I Vertommen; L G Van Nueten
Journal:  Eur J Clin Pharmacol       Date:  1997       Impact factor: 2.953

9.  Effect of nebivolol or atenolol vs. placebo on cardiovascular health in subjects with borderline blood pressure: the EVIDENCE study.

Authors:  Daniel A Duprez; Natalia Florea; Sue Duval; Catherine Koukol; Jay N Cohn
Journal:  J Hum Hypertens       Date:  2017-11-28       Impact factor: 3.012

Review 10.  Drug Treatment of Hypertension: Focus on Vascular Health.

Authors:  Alan C Cameron; Ninian N Lang; Rhian M Touyz
Journal:  Drugs       Date:  2016-10       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.